tbuckley/cabot-search huggingface dataset:
Internal Medicine
Authors: Alfred Soffer
Journal: JAMA (1978)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE RELATIONS BETWEEN MEAT POISONING AND PARATYPHOID FEVER.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Munchausen Patient
Authors: JOHN T. FLYNN
Journal: Annals of Internal Medicine (1973)

Letters, Comments, and Corrections1 February 1973Munchausen PatientJOHN T. FLYNN, M.D.JOHN T. FLYNN, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-78-2-315_3 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: A young woman in her mid-twenties was recently admitted to the Beekman Downtown Hospital New York, N.Y., with abscesses of the buttocks and a story of a lymph-node biopsy positive for Hodgkin's disease in Manchester, England, at some time during the preceding 6 months. During her hospital stay, her addiction to parenteral pentazocine (Talwin®) became evident; the diagnosis of Hodgkin's disease was not confirmed by inquiry to hospitals in Manchester; and syringes and needles were found in her bedside table, apparently for self-administered unsterile injections into the buttocks.With slight... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byMunchausen’s syndrome: report of case 1 February 1973Volume 78, Issue 2Page: 315-315KeywordsAbscessesBiopsyHodgkin lymphoma Issue Published: 1 February 1973 PDF downloadLoading ...
C-reactive protein: a critical update
Authors: M. B. Pepys
Journal: Journal of Clinical Investigation (2003)

However, it is critically important to recognize that the CRP response is nonspecific and is triggered by many disorders unrelated to cardiovascular disease (Table 2).In using CRP for assessment of cardiovascular risk, it is therefore essential to clearly establish true base-line CRP values that are not distorted by either trivial or serious intercurrent pathologies.If the initial CRP result is in the low-risk range, less than 1 mg/l, a single measurement is sufficient, but if it is in the higher-risk range, greater than about 2.5 mg/l, two or more serial samples taken at intervals of 1 week or more should be retested until a stable base-line value is seen.If the CRP value persistently remains above 10 mg/l, indicating the presence of a significant acute-phase response, a full history and physical examination of the patient is indicated, ideally together with relevant investigations, to determine the cause and alleviate it if possible.Interestingly, chronic inflammatory conditions, such as rheumatoid arthritis and hemodialysis for end-stage renal failure, that are characterized by persistently elevated CRP concentrations in some individuals, are associated with premature cardiovascular disease.
From the Editors
Authors: T. Gansler, O. W. Brawley
Journal: CA A Cancer Journal for Clinicians (2008)

Starting with this issue, we will be publishing full-text HTML articles and other content to the CA Web site in advance of the printed version of the journal in a new feature called CA First Look. This feature is intended to provide CA's content to our readers as quickly as possible. The online publication date is posted on each HTML article and is the date of record for publication. Readers should be aware that content published in CA First Look is the final version that has been peer-reviewed, revised, edited, and approved by the authors. When a complete issue of CA is posted online, the issue's content is removed from the CA First Look index and moved to the table of contents for that issue, at which point the articles will be available as PDFs. Every year since 1967, the American Cancer Society (ACS) has published the annual “Cancer Statistics” article in CA. During this period, clinicians have turned to this article for a concise summary of the most up-to-date cancer incidence, mortality, and survival data, as well as estimates of new cancer cases and deaths for the current year based on incidence data from the Surveillance, Epidemiology, and End Results program of the National Cancer Institute and mortality data from the National Center for Health Statistics (NCHS) of the Centers for Disease Control and Prevention. Due to a delayed release of mortality data from the NCHS, we regret that “Cancer Statistics, 2008” will not appear in this issue, but in a future issue. The annual “Cancer Statistics” article continues to be one of the most important articles published in CA. We are working closely with NCHS staff to get it published as soon as possible. Every year since 2000, the ACS has published an article on our “Guidelines for the Early Detection of Cancer.” These articles, especially in the past several years, have included an overview of current guidelines, a review of any guideline revisions made during the prior calendar year, a summary of recent research relevant to early detection of cancer, and population-based information on prevalence of testing. Although this article has usually appeared in our January/February issue, this year it will appear later so that it will incorporate the new colorectal screening guidelines when they are published. Sincerely, Ted Gansler, MD, MBA Editor, CA: A Cancer Journal for Clinicians Otis Webb Brawley, MD Editor-in-Chief, CA: A Cancer Journal for Clinicians
Scandinavian Journal Clin &amp;amp; Lab Invest, Oslo
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Recombinant follicle stimulating hormone: development of the first biotechnology product for the treatment of infertility
Journal: Human Reproduction Update (1998)

Genes encoding the common gonadotrophin α subunit and follicle stimulating hormone (FSH)-specific β subunit were isolated from a DNA library derived from human fetal liver cells, and inserted into separate expression vectors containing a selectable/amplifiable gene. These vectors were inserted into the genome of the Chinese hamster ovary cell line, resulting in expression of large amounts of biologically active human (h)FSH. This cell line was cultured on microcarrier beads in a large-scale bioreactor. hFSH in the cell culture supernatant was purified to homogeneity by a multistep process. The mature β subunit had seven fewer amino acid residues than reported in the literature and three other differences were found in the sequence. Similar oligosaccharide structures were present on recombinant (r)-hFSH and a purified urinary (u)-hFSH preparation. In-vitro and in-vivo, the biological activities of u- and r-hFSH were indistinguishable, r-hFSH was formulated in ampoules containing 75 IU FSH activity ( 7.5 μg FSH), which accounts for >99% of the protein content of the preparation. Studies in non-human primates and human volunteers showed the pharmacokinetics of u- and r-hFSH to be similar. In healthy volunteers, r-hFSH stimulated follicular development and induced significant increases in serum oestradiol and inhibin. Clinical experience with r-hFSH has shown it is more effective at stimulating ovarian follicle growth than urinary gonadotrophins. It is also effective at initiating spermatogenesis when given together with human chorionic gonadotrophin.
OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.
Authors: Robert Hans Ingemar Andtbacka, Frances A. Collichio, Thomas Amatruda, Neil N. Senzer, Jason Chesney, Keith A. Delman, Lynn E. Spitler, Igor Puzanov, Susan Doleman, Yining Ye, Ari M. Vanderwalde, Robert Coffin, Howard Kaufman
Journal: Journal of Clinical Oncology (2013)

LBA9008 Background: T-VEC is an oncolytic immunotherapy (OI) derived from herpes simplex virus type-1 designed to selectively replicate within tumors and to produce GM-CSF to enhance systemic antitumor immune responses. OPTiM is a randomized, phase III trial of T-VEC or GM-CSF in patients (pts) with unresected melanoma with regional or distant metastases. We report the primary results of the first phase III study of OI. Methods: Key criteria: age ≥18 yrs; ECOG ≤1; unresectable melanoma stage IIIB/C or IV; injectable cutaneous, SC, or nodal lesions; LDH ≤1.5X upper limit of normal; ≤3 visceral lesions (excluding lung), none &gt;3 cm. Pts were randomized 2:1 to intralesional T-VEC (initially ≤ 4 mL x10 6 pfu/mL then after 3 wks, ≤ 4 mL x10 8 pfu/mL Q2W) or SC GM-CSF (125 µg/m 2 qd x 14 days q28d). The primary endpoint was durable response rate (DRR): partial or complete response (CR) continuously for ≥6 mos starting within 12 mos. Responses were per modified WHO by blinded central review. A planned interim analysis of overall survival (OS; key secondary endpoint) was performed. Results: 436 pts are in the ITT set: 295 (68%) T-VEC, 141 (32%) GM-CSF. 57% were men; median age was 63 yrs. Stage distribution was: IIIB/C 30%, IVM1a 27%, IVM1b 21%, IVM1c 22%. Objective response rate with T-VEC was 26% (95% CI: 21%, 32%) with 11% CR, and with GM-CSF was 6% (95% CI: 2%, 10%) with 1% CR. DRR for T-VEC was 16% (95% CI: 12%, 21%) and 2% for GM-CSF (95% CI: 0%, 5%), p&lt;0.0001. DRR by stage (T-VEC, GM-CSF) was IIIB/C (33%, 0%), M1a (16%, 2%), M1b (3%, 4%), and M1c (8%, 3%). Interim OS showed a trend in favor of T-VEC; HR 0.79 (95% CI: 0.61, 1.02). Most common adverse events (AEs) with T-VEC were fatigue, chills, and pyrexia. Serious AEs occurred in 26% of T-VEC and 13% of GM-CSF pts. No ≥ grade 3 AE occurred in ≥ 3% of pts in either arm. Conclusions: T-VEC demonstrated both a statistically significant improvement in DRR over GM-CSF in pts with unresectable stage IIIB-IV melanoma and a tolerable safety profile; an interim analysis showed a trend toward improved OS. T-VEC represents a novel potential tx option for melanoma with regional or distant metastases. Clinical trial information: NCT00769704.
Hypoglycemia
Authors: Rachmiel Levine
Journal: JAMA (1974)

IT IS undoubtedly very attractive and satisfying to believe in one plausible and "scientific" biological explanation for feelings of fatigue, weakness, dizzy spells, and exhaustion. This set of symptoms is such a common affliction of mankind that it begs for an explanation in terms of an easily understood chemical change in the body. The modern concept is to blame it all on<i>low blood sugar levels</i>. There is no doubt that periods of true low blood sugar concentrations (hypoglycemia) may produce such symptoms, and, in those cases, raising the blood sugar level back to normal relieves the individual. Hypoglycemia means, literally, less sugar in the blood.<i>Thus, it is a laboratory finding, not a disorder</i>. However, soon after insulin came into therapeutic use (about 1924), it was found that a "low" blood sugar concentration causes a characteristic train of symptoms: anxiety, tremor, perspiration, dizziness, palpitations, confusion, lethargy, and ultimately loss
Reply
Authors: Angels Escorsell, Jaime Bosch
Journal: Hepatology (2016)

Potential conflict of interest: Nothing to report. We read with interest the letter from Dai and coworkers related to the potential reflux‐related complications of esophageal stents. However, the complications the authors described were related to long‐term esophageal stents used to treat benign or malign strictures of the esophagus, which is not the case. In fact, the stents used to control acute esophageal variceal bleeding are specifically designed for this severe complication and are removable stents, which can remain in place from 6 to 14 days. Moreover, they were also used to treat esophageal tears caused by a previous balloon tamponade.1 As stated by the authors, all patients developing acute variceal bleeding are placed in a slightly upright position to avoid aspiration of the gastric content, which, unfortunately, occurred in one patient in the stent group. However, this adverse event could be attributed to the presence of hematemesis, upper endoscopy, placement of the stent, etc. As mentioned in the article, aspiration was more frequent in the group of patients treated by esophageal balloon tamponade than in those receiving esophageal metal stents.
Harbingers of Rejection
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
COPD
Authors: I. Gültuna, P. E. M. Huygen, H. Strijdhorst, C. Ince, H. A. Bruining, A. De Monte, F. Baigorri, P. Saura, L. Blanch, R. Fernàndez, A. Artigas, L. I. Blanch, R. Fernandez, F. Baigorri, A. DeMonte, A. Artigas, L. Appendini, S. Zanaboni, A. Patessio, B. Gukov, C. F. Donner, A. Rossi, F. Maltais, M. Sovili, V. M. Ranieri, P. Navalese, S. B. Gottfried, P. Baconnier, A. Eberhard, P. Y. Carry, J. P. Perdrix, J. M. Fargnoli, F. Coppo
Journal: Intensive Care Medicine (1992)
HISTOLOGIC DIFFERENTIATION BETWEEN TUBERCULOSIS AND SYPHILIS.
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE INTRODUCTION OF NEW DRUGS
Journal: JAMA (1929)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The 1941 Year Book of Pathology and Immunology
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Comparison of reports of randomized controlled trials and systematic reviews in surgical journals: literature review
Authors: Sukhmeet Singh Panesar, Ricky Thakrar, Thanos Athanasiou, Aziz Sheikh
Journal: Journal of the Royal Society of Medicine (2006)

Objectives Randomized controlled trials and systematic reviews of such trials are the gold standard for assessing the effectiveness of interventions. There have been concerns about the anecdotal evidence underpinning many of the interventions used and introduced into surgical care. The American College of Surgeons has prioritized the need for more trials and systematic reviews of trials. To investigate the assertion that the methodological quality of studies conducted in surgery is in general poor and to assess the possible impact of new policy developments in the US, we sought to compare the number and proportion of published randomized controlled trials and systematic reviews in the leading two US and UK general surgical journals. Two reviewers systematically and independently hand searched all issues of these journals over a 12-month period to identify randomised controlled trials and systematic reviews. Design Systematic searching and independent abstraction of data from all volumes of the top two general surgical journals published in the USA and the UK in 2004. Setting 519 original reports in UK journals and 616 original reports in USA journals. Main Outcome Measures Number and proportion of randomized controlled trials and systematic reviews. Results Overall, the proportion of randomized controlled trials in all four journals was 5.6% (95% confidence interval [CI] 4.4–7.0) and 5.2% (95% CI 4.1–6.7) for systematic reviews. For journals published in the UK 29/519 (5.6%) of the publications were reports of randomized controlled trials, and for the USA journals this figure was 34/616 (5.5%); odds ratio [OR]=0.99, 95%CI 0.6–1.6; P=0.96. Systematic reviews were significantly more commonly reported in the UK journals: UK 37/519 (7.1%) versus USA 22/616 (3.6%); OR=0.48, 95%CI 0.3–0.8; P&lt;0.01. Conclusions The concerns expressed almost a decade ago remain valid: there are still very few reports of randomized controlled trials and systematic reviews published in leading USA and UK surgical journals, with relatively little difference between these countries in the proportion of reported studies employing these designs. The American College of Surgeons initiative has yet to make an impact.